TITLE

Klinička značajnost otkrivanja mutacije T31 51 u domeni ABL kinaze kod bolesnika rezistentnih na liječenje imatinib mesilatom

AUTHOR(S)
Horvat, Ivana; AntoIic, Margareta Radic; Zadro, Renata; Sertic, Dubravka; Labar, Boris
PUB. DATE
April 2010
SOURCE
Biochemia Medica;2010, Vol. 20 Issue 1, p75
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of bcr-abl fusion gene and consequently bcr-abl fusion protein. Although the discovery of tyrosine kinase inhibitor (TKI), imatinib mesylate (IM), improved the treatment of CML patients, a proportion of patients develop resistance to the drug resulting in increased bcr-abl level. One of possible reasons for resistance are the mutations in ABL kinase domain. Some mutations can be overcome by increasing the drug dose or by using the new generation of TKI. The only mutation resistant to currently available IKI is T3151. The aim of this study was to detect if the presence of T3151 in patients resistant to imatinib mesylate therapy is associated with the increase or constantly high bcr-abl level. We also aimed to assess the possible difference in bcr-abl level in imatinib-resistant patients with and without T3151 mutation. Materials and methods: The study included 24 CML patients with inadequate response to IM therapy. Real time quantitative PCR was performed according to Europe Against Cancer protocol and allele specific oligonucleotide PCR was used for T3151 mutation detection. Results: 13151 was detected in 4 out of 24 patients (17%). Calculated median bcr-abl/abl levels were 19% for T3151 positive and 13% for T3151 negative patients, but the difference was not statistically significant (P = 0.394). Conclusions: T3151 detection is essential in therapy approach for CML patients as the treatment of choice for T3151 carriers is stem-cell transplantation.
ACCESSION #
49313492

 

Related Articles

  • Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Wei, Yuan; Hardling, Mats; Olsson, Bob; Hezaveh, Rahil; Ricksten, Anne; Stockelberg, Dick; Wadenvik, Hans // Annals of Hematology;Dec2006, Vol. 85 Issue 12, p841 

    Point mutations within the ABL kinase domain of the BCR- ABL gene are associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML). To obtain more information about the association between BCR- ABL mutations and type of imatinib resistance, we studied 30 early...

  • Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Wetzler, Meir; Segal, David // Current Pharmaceutical Design;1/1/2011, Vol. 17 Issue 1, p59 

    No abstract available.

  • Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Shah, Neil P. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p49 

    The small molecule BCR-ABL-selective kinase inhibitor imatinib is the single most effective medical therapy for the treatment of chronic myeloid leukemia (CML). Although imatinib is highly effective initially and generally well tolerated, for patients who undergo relapse or disease progression...

  • Dasatinib for CML Blast Phase after Imatinib Failure. Artz, Andrew S. // Clinical Oncology Alert;Feb2009, Vol. 25 Issue 2, p11 

    Chronic myelogenous leukemia (cml) is typically considered a triphasic disease. It often presents in chronic phase and, without treatment, progresses to accelerated and/or blast phase. The blast phase can be immunophenotypically characterized as myeloid in approximately 70% of cases and lymphoid...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • Nilotinib, dasatinib or imatinib in CML: no clear winner. Cooper, Nick // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p7 

    Chronic myeloid leukaemia (CML) is characterised by three distinct phases: chronic phase (CP), accelerated phase (AP) and blast crisis (BC). CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as the first- generation imatinib [Glivec] and the newer second-generation...

  • Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Villuendas, R.; Steegmann, J. L.; Pollán, M.; Tracey, L.; Granda, A.; Fernández-Ruiz, E.; Casado, L. F.; Martínez, J.; Martínez, P.; Lombardía, L.; Villalón, L.; Odriozola, J.; Piris, M. A. // Leukemia (08876924);Jun2006, Vol. 20 Issue 6, p1047 

    The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the BCR–ABL fusion protein, has represented a critical advance in chronic myeloid leukemia (CML) treatment. However, a subset of patients initially fails to respond to this treatment. Use of...

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

  • Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Dalziel, Kim; Round, Ali; Garside, Ruth; Stein, Ken // PharmacoEconomics;2005, Vol. 23 Issue 5, p515 

    Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-alpha or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.Design and Setting: A cost-utility (Markov) model within the setting of the UK NHS and viewed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics